Unfortunately, GLP1 RAs are not yet approved for non-diabetic patients, while SGLT2i can be used in patients with no T2DM only under the presence of heart or renal failure, urging as mandatory the conduction of extended trials with these drugs in NAFLD patients with no T2DM. Here, GCG is linked to Renal insufficiency.